Orphazyme A/S
ORPH
ORPH was delisted on the 30th of March, 2022.
16 hedge funds and large institutions have $37.9M invested in Orphazyme A/S in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
10.51% more ownership
Funds ownership: 0% → 10.51% (+11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IM
Islet Management
New York
|
+$13.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$5.3M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$4.91M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2M |
| 5 |
Millennium Management
New York
|
+$1.98M |
Top Sellers
ORPH Hedge Fund Activity: Q3 2020 in Review
16 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Orphazyme A/S (ORPH) for Q3 2020, worth a combined $37.9M.
Buyers outnumbered sellers: 16 funds opened new ORPH positions and 0 closed out — a net gain of 16 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Islet Management, opening a new position worth an estimated $13.6M.
- 16 institutional investors held Orphazyme A/S (ORPH) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $37.9M of Orphazyme A/S stock for Q3 2020.
- 16 funds opened new Orphazyme A/S positions in Q3 2020 and 0 closed out, a net change of +16 holders.
- The largest Orphazyme A/S buyer in Q3 2020 was Islet Management, an estimated $13.6M added.
Based on aggregated 13F filings for Q3 2020.